ObsEva SA (OBSV)

[Frankestin]

https://www.obseva.com/pressrelease-detail/?pr=4786

Once daily linzagolix 200 mg with ABT met both co-primary efficacy objectives, demonstrating reductions in dysmenorrhea and non-menstrual pelvic pain versus placebo at 3 months; showed statistically significant and clinically meaningful improvements versus placebo in ranked secondary endpoints of dysmenorrhea, non-menstrual pelvic pain, dyschezia, overall pelvic pain, and ability to perform daily activities at 6 months-

Ongoing for up to an additional 6 months
https://clinicaltrials.gov/ct2/show/NCT04335591

Where will they decide to take it?